Victory Capital Management
GYRE icon

Victory Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Victory Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-739
Closed -$24K – 2830
2020
Q1 		$24K Buy
+739
New +$34K ﹤0.01% 3032
2019
Q4 		– Sell
-270
Closed -$10K – 2900
2019
Q3 		$10K Buy
+270
New +$14.6K ﹤0.01% 3257

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Victory Capital Management's GYRE Position: Q2 2020 in Review

Victory Capital Management sold out of Gyre Therapeutics (GYRE) in Q2 2020, closing a stake of 739 shares — an estimated $24K sold.

Victory Capital Management first reported a position in GYRE in Q3 2019 and held it in 2 quarters. The position peaked at $24K in Q1 2020. 79 funds tracked by Wall St. Rank hold GYRE as of Q2 2020.

  • Victory Capital Management reported no remaining Gyre Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 739 Gyre Therapeutics shares in Q2 2020, an estimated $24K.
  • Victory Capital Management first reported a position in Gyre Therapeutics in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Gyre Therapeutics position peaked at $24K in Q1 2020.
  • 79 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.